Combination treatment for visceral leishmaniasis patients co-infected with human immunodeficiency virus in India

S. Burza
2016 International Journal of Infectious Diseases  
SHORT SUMMARY (40 words): We describe the safety and efficacy of treating visceral leishmaniasis in patients with HIV-VL coinfection with concurrent intravenous liposomal amphotericin B (AmBisome) and oral miltefosine (Impavido) in India. The regimen was safe, well tolerated, with lower relapse rates than monotherapy. ABSTRACT Background There are considerable numbers of patients co-infected with Human Immunodeficiency Virus (HIV) and Visceral Leishmaniasis (VL) in the VL-endemic areas of
more » ... emic areas of Bihar, India. These patients are at higher risk of relapse and death, but there are still no evidence-based guidelines on how to treat them. In this study, we report on treatment outcomes of co-infected patients up to 18 months following treatment with a combination regimen.
doi:10.1016/j.ijid.2016.02.166 fatcat:lmeimlz42vcehih4p36n7swt2q